Evogene Ltd. (EVGN)

NCM – Real Time Price. Currency in USD

0.39

-0.01 (-2.31%)

At close: Jun 26, 2026, 4:00 PM EDT

0.39

+0.00 (0.36%)

After-hours: Jun 26, 2026, 7:37 PM EDT

09.06.2026

Evogene to Present Its Pharma Division Achievements at the BIO International Convention

Conference to be held in San Diego, CA, USA – June 22-25, 2026 REHOVOT, Israel, June 9, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneering company in computational chemistry specializing in AI-based generative design of small molecules for the pharmaceutical and agricultural industries, today announced that it will be featured as a presenting company at the upcoming BIO International Convention, to be held on June 22-25, in San Diego, USA.

02.06.2026

Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica

Study Results Demonstrated Favorable Safety Profile and Preliminary Signals of Clinical Activity REHOVOT, Israel, June 2, 2026 /PRNewswire/ -- Evogene Ltd. ("Evogene") (Nasdaq: EVGN) (TASE: EVGN), a pioneering computational chemistry company specializing in generative design of small molecules for the pharmaceutical and agricultural industries, today announced the successful completion of the first-in-human (FIH) Phase 1 clinical study of BMC128, a rationally-designed live bacterial product developed by its subsidiary, Biomica Ltd.

29.05.2026

EverGen Infrastructure Corp. (EVGN:CA) Q1 2026 Earnings Call Transcript

20.05.2026

Evogene Ltd. (EVGN) Q1 2026 Earnings Call Transcript

20.05.2026

Evogene Reports First Quarter 2026 Financial Results

Conference call and webcast: today, May 20, 2026, 9:00 AM ET REHOVOT, Israel, May 20, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneering company in computational chemistry specializing in the generative AI design of small molecules for the pharmaceutical and agricultural industries, today announced its financial results for the first quarter ended March 31, 2026.

12.05.2026

Evogene to Present at the 24th Schrödinger European User Group Meeting

Conference will be held in Munich, Germany - May 19-21, 2026 REHOVOT, Israel, May 12, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneering company in computational chemistry specializing in the generative AI design of small molecules for the pharmaceutical and agricultural industries, today announced its participation in the 24th Schrödinger European User Group Meeting, taking place May 19–21, 2026, in Munich, Germany.

07.05.2026

Evogene Schedules First Quarter 2026 Financial Results Release

Zoom conference call scheduled for May 20, 2026, 9:00 AM ET REHOVOT, Israel, May 7, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneering company in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, announced today that it will release its financial results for the first quarter 2026, on Wednesday , May 20 , 2026.

Videos

No Data

There is no data to display

Press releases

02.06.2026

Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica

20.05.2026

Evogene Reports First Quarter 2026 Financial Results

02.04.2026

Evogene Reports Receipt of Nasdaq Minimum Bid Price Notification

REHOVOT, Israel, April 2, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN)(TASE: EVGN) (the "Company", "Evogene"), a pioneering company in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries, today reported that the Company received a letter (the "Letter") from the Nasdaq Stock Market LLC ("Nasdaq"), indicating that the Company is currently not in compliance with Nasdaq Rule 5550(a)(2), as the Company's closing bid price for its ordinary shares has been below $1.00 per share for 30 consecutive business days.

31.03.2026

Casterra Announces Successful Commercial Field Trials in Brazil, Positioning Castor Oil as a Promising Candidate for Economically Viable Biofuel Feedstock

Today, castor oil is a premium sustainable industrial feedstock for bio-based products REHOVOT, Israel, March 31, 2026 /PRNewswire/ -- Casterra Ag Ltd. ("Casterra"), a developer of high-yield castor seed varieties and integrated castor farming solutions, and a subsidiary of Evogene Ltd.

Evogene Ltd. (EVGN)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Evogene Ltd. (EVGN)

Evogene to Present Its Pharma Division Achievements at the BIO International Convention

Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica

EverGen Infrastructure Corp. (EVGN:CA) Q1 2026 Earnings Call Transcript

Evogene Ltd. (EVGN) Q1 2026 Earnings Call Transcript

Evogene Reports First Quarter 2026 Financial Results

Evogene to Present at the 24th Schrödinger European User Group Meeting

Evogene Schedules First Quarter 2026 Financial Results Release

Videos

No Data

Press releases

Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica

Evogene Reports First Quarter 2026 Financial Results

Evogene Reports Receipt of Nasdaq Minimum Bid Price Notification

Casterra Announces Successful Commercial Field Trials in Brazil, Positioning Castor Oil as a Promising Candidate for Economically Viable Biofuel Feedstock

Evogene to Present Its Pharma Division Achievements at the BIO International Convention

Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica

EverGen Infrastructure Corp. (EVGN:CA) Q1 2026 Earnings Call Transcript

Evogene Ltd. (EVGN) Q1 2026 Earnings Call Transcript

Evogene Reports First Quarter 2026 Financial Results

Evogene to Present at the 24th Schrödinger European User Group Meeting

Evogene Schedules First Quarter 2026 Financial Results Release

Videos

No Data

Press releases

Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica

Evogene Reports First Quarter 2026 Financial Results

Evogene Reports Receipt of Nasdaq Minimum Bid Price Notification

Casterra Announces Successful Commercial Field Trials in Brazil, Positioning Castor Oil as a Promising Candidate for Economically Viable Biofuel Feedstock

Search stocks

Evogene Ltd. (EVGN)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Evogene Ltd. (EVGN)

Evogene to Present Its Pharma Division Achievements at the BIO International Convention

Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica

EverGen Infrastructure Corp. (EVGN:CA) Q1 2026 Earnings Call Transcript

Evogene Ltd. (EVGN) Q1 2026 Earnings Call Transcript

Evogene Reports First Quarter 2026 Financial Results

Evogene to Present at the 24th Schrödinger European User Group Meeting

Evogene Schedules First Quarter 2026 Financial Results Release

Videos

No Data

Press releases

Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica

Evogene Reports First Quarter 2026 Financial Results

Evogene Reports Receipt of Nasdaq Minimum Bid Price Notification

Casterra Announces Successful Commercial Field Trials in Brazil, Positioning Castor Oil as a Promising Candidate for Economically Viable Biofuel Feedstock

Evogene to Present Its Pharma Division Achievements at the BIO International Convention

Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica

EverGen Infrastructure Corp. (EVGN:CA) Q1 2026 Earnings Call Transcript

Evogene Ltd. (EVGN) Q1 2026 Earnings Call Transcript

Evogene Reports First Quarter 2026 Financial Results

Evogene to Present at the 24th Schrödinger European User Group Meeting

Evogene Schedules First Quarter 2026 Financial Results Release

Videos

No Data

Press releases

Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica

Evogene Reports First Quarter 2026 Financial Results

Evogene Reports Receipt of Nasdaq Minimum Bid Price Notification

Casterra Announces Successful Commercial Field Trials in Brazil, Positioning Castor Oil as a Promising Candidate for Economically Viable Biofuel Feedstock